Macquarie Group’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$137M Buy
1,082,366
+71,760
+7% +$9.45M 0.59% 28
2026
Q1
$141M Sell
1,010,606
-98,542
-9% -$13.8M 0.84% 19
2025
Q4
$136M Sell
1,109,148
-479,391
-30% -$58.3M 0.6% 25
2025
Q3
$176M Buy
1,588,539
+146,312
+10% +$16.6M 0.21% 84
2025
Q2
$160M Sell
1,442,227
-59,485
-4% -$6.33M 0.2% 99
2025
Q1
$168M Buy
1,501,712
+46,878
+3% +$4.84M 0.21% 109
2024
Q4
$130M Buy
1,454,834
+60,957
+4% +$5.49M 0.16% 176
2024
Q3
$117M Buy
1,393,877
+152,296
+12% +$11.6M 0.13% 222
2024
Q2
$85.2M Sell
1,241,581
-17,203
-1% -$1.15M 0.1% 269
2024
Q1
$92.2M Buy
1,258,784
+5,592
+0.4% +$430K 0.1% 256
2023
Q4
$102M Buy
1,253,192
+82,982
+7% +$6.46M 0.12% 243
2023
Q3
$87.7M Buy
1,170,210
+8,411
+0.7% +$647K 0.11% 250
2023
Q2
$89.5M Sell
1,161,799
-23,903
-2% -$1.91M 0.1% 260
2023
Q1
$98.4M Buy
1,185,702
+55,231
+5% +$4.57M 0.12% 235
2022
Q4
$97.1M Buy
1,130,471
+12,401
+1% +$982K 0.11% 250
2022
Q3
$69M Buy
1,118,070
+12,509
+1% +$789K 0.08% 326
2022
Q2
$68.3M Sell
1,105,561
-3,884
-0.4% -$240K 0.08% 357
2022
Q1
$66K Buy
1,109,445
+459,138
+71% +$29.3M 0.05% 430
2021
Q4
$47.2M Buy
650,307
+4,284
+0.7% +$295K 0.04% 534
2021
Q3
$45.1M Buy
646,023
+277,434
+75% +$19.5M 0.04% 559
2021
Q2
$25.4M Buy
368,589
+112,970
+44% +$7.54M 0.02% 714
2021
Q1
$16.5M Sell
255,619
-110,145
-30% -$7.1M 0.02% 593
2020
Q4
$21.3M Buy
365,764
+6,000
+2% +$362K 0.03% 498
2020
Q3
$22.7M Buy
359,764
+22,409
+7% +$1.55M 0.04% 437
2020
Q2
$26M Sell
337,355
-76,376
-18% -$5.85M 0.04% 412
2020
Q1
$30.9M Buy
413,731
+14,395
+4% +$995K 0.06% 317
2019
Q4
$25.9M Buy
399,336
+5,806
+1% +$378K 0.04% 444
2019
Q3
$24.9M Sell
393,530
-805
-0.2% -$52.6K 0.04% 400
2019
Q2
$26.6M Sell
394,335
-8,777
-2% -$577K 0.04% 389
2019
Q1
$26.2M Sell
403,112
-17,197
-4% -$1.14M 0.04% 405
2018
Q4
$26.3M Sell
420,309
-22,993
-5% -$1.61M 0.05% 366
2018
Q3
$34.2M Buy
443,302
+28,450
+7% +$2.15M 0.06% 356
2018
Q2
$29.4M Buy
414,852
+29,375
+8% +$2.07M 0.05% 391
2018
Q1
$29.1M Sell
385,477
-9,677
-2% -$769K 0.05% 377
2017
Q4
$27.7M Sell
395,154
-84,178
-18% -$6.39M 0.05% 393
2017
Q3
$38.8M Buy
479,332
+100,741
+27% +$7.7M 0.07% 275
2017
Q2
$26.8M Sell
378,591
-59,556
-14% -$3.96M 0.05% 376
2017
Q1
$29.8M Sell
438,147
-54,603
-11% -$3.84M 0.05% 340
2016
Q4
$35.3M Sell
492,750
-18,391
-4% -$1.37M 0.07% 261
2016
Q3
$40.4M Sell
511,141
-655,093
-56% -$53.2M 0.08% 228
2016
Q2
$97.3M Buy
1,166,234
+535,550
+85% +$47.5M 0.1% 171
2016
Q1
$57.9M Sell
630,684
-63,653
-9% -$5.74M 0.12% 136
2015
Q4
$70.3M Sell
694,337
-53,070
-7% -$5.52M 0.14% 116
2015
Q3
$73.4M Sell
747,407
-4,997
-0.7% -$555K 0.16% 112
2015
Q2
$88.1M Sell
752,404
-266,895
-26% -$29.2M 0.17% 110
2015
Q1
$100M Sell
1,019,299
-10,269
-1% -$1.04M 0.2% 100
2014
Q4
$97M Sell
1,029,568
-92,044
-8% -$9.52M 0.2% 98
2014
Q3
$119M Sell
1,121,612
-147,993
-12% -$14.5M 0.26% 88
2014
Q2
$105M Buy
1,269,605
+224,375
+21% +$17.5M 0.23% 101
2014
Q1
$74.1M Sell
1,045,230
-34,651
-3% -$2.72M 0.13% 128
2013
Q4
$81.1M Sell
1,079,881
-7,023
-0.6% -$489K 0.15% 117
2013
Q3
$68.3M Sell
1,086,904
-56,485
-5% -$3.38M 0.13% 123
2013
Q2
$58.6M Buy
+1,143,389
New +$59.6M 0.13% 130

Other funds holding GILD

Macquarie Group's GILD Position: Q2 2026 in Review

Macquarie Group increased its Gilead Sciences (GILD) stake by 7.1% in Q2 2026, buying an estimated $9.45M and bringing the position to 1,082,366 shares worth $137M. The position accounts for 0.59% of the portfolio, ranked #28.

Macquarie Group first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $176M in Q3 2025. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Macquarie Group held 1,082,366 shares of Gilead Sciences worth $137M as of Q2 2026.
  • Macquarie Group bought 71,760 Gilead Sciences shares in Q2 2026, an estimated $9.45M.
  • Gilead Sciences made up 0.59% of Macquarie Group's portfolio in Q2 2026, its #28 holding.
  • Macquarie Group first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Macquarie Group's Gilead Sciences position peaked at $176M in Q3 2025.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Macquarie Group's 13F filing for Q2 2026, filed 14 Aug 2026.